Ventilator-Associated Pneumonia (Pneumonia, Ventilator Associated)

Subscribe to Selected New Research on Ventilator-Associated Pneumonia

1093 relevant articles (39 outcomes, 179 trials/studies) found for this Disease

Description: Serious INFLAMMATION of the LUNG in patients who required the use of PULMONARY VENTILATOR. It is usually caused by cross bacterial infections in hospitals (NOSOCOMIAL INFECTIONS).

Also Known As:

Pneumonia, Ventilator Associated; Pneumonia, Ventilator-Associated; Ventilator Associated Pneumonia

Relationship Network

Disease Context: Research Results

Bacterial Infections and Mycoses

Infection: 225242

Cross Infection: 2472

Ventilator-Associated Pneumonia: 1093

Respiratory Tract Diseases: 377

Lung Diseases: 8942

Pneumonia: 17859

Ventilator-Associated Pneumonia: 1093

Lung Injury: 6035

Ventilator-Induced Lung Injury: 242

Ventilator-Associated Pneumonia: 1093

Respiratory Tract Infections: 5595

Pneumonia: 17859

Ventilator-Associated Pneumonia: 1093

Related Diseases

1.	Pneumonia (Pneumonitis)
2.	Urinary Tract Infections (Urinary Tract Infection)
3.	Chronic Obstructive Pulmonary Disease (COPD)
4.	Neoplasms (Cancer)
5.	Burns

Experts

1.	Chastre, Jean: 7 articles (08/2008 - 01/2005)
2.	Kollef, Marin H: 5 articles (08/2008 - 01/2004)
3.	Schultz, Marcus J: 5 articles (08/2008 - 01/2004)
4.	Fabian, Timothy C: 5 articles (02/2007 - 06/2002)
5.	Croce, Martin A: 5 articles (02/2007 - 06/2002)
6.	Luyt, Charles-Edouard: 4 articles (08/2008 - 01/2005)
7.	Breilh, Dominique: 4 articles (05/2008 - 07/2005)
8.	Allaouchiche, Bernard: 4 articles (05/2008 - 01/2002)
9.	Wood, G Christopher: 4 articles (01/2005 - 06/2002)
10.	Boucher, Bradley A: 4 articles (01/2005 - 06/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Ventilator-Associated Pneumonia:

1.	VAP combinationIBA 02/01/2004 - "The best route of nutrition in the acute phase, actual efficacy of immune system-enhancing diets, and the prevention of bacterial translocation (BT) and Ventilator-associated pneumonia (VAP) should be resolved. " 03/29/2008 - "Seven randomized clinical trials have been published that showed a significant reduction in ventilator associated pneumonia (VAP) incidence, but not on survival. " 08/01/2008 - "BACKGROUND: Accurate diagnosis and appropriate treatment of ventilator associated pneumonia (VAP) is crucial for good outcomes. " 04/01/2006 - "Our goal was to describe the successful application of PBL to patient care improvement with development of an algorithm for the empiric therapy of ventilator-associated pneumonia (VAP). " 09/01/2007 - "BACKGROUND: Several interventions have been shown to be effective in reducing the incidence of ventilator-associated pneumonia (VAP), but their implementation in clinical practice has not gained widespread acceptance. " Order ALL the reference details at left...
2.	Colistin (Coly-Mycin)FDA Link 08/01/2007 - "Colistin-susceptible ventilator-associated pneumonia episodes can be effectively treated using colistin without significant renal dysfunction. " 01/01/2009 - "[Colistin use in ventilator-associated pneumonia due to panresistant Pseudomonas aeruginosa and Acinetobacter baumannii]" 10/01/2008 - "Ventilator-associated pneumonia with Col-S strains: a successful comeback of colistin!" 03/01/2008 - "Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study." 12/01/2007 - "Colistin as a first choice antibiotic for the initial empiric antimicrobial therapy of ventilator-associated pneumonia." Order ALL the reference details at left...
3.	meropenem (Merrem)FDA Link 02/01/2001 - "Efficacy of meropenem as monotherapy in the treatment of ventilator-associated pneumonia." 01/01/2001 - "[Efficacy of monotherapy by meropenem in ventilator-associated pneumonia]" 03/01/2009 - "Experience with extended-infusion meropenem in the management of ventilator-associated pneumonia due to multidrug-resistant Acinetobacter baumannii." 02/01/2006 - "Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli." 04/01/2005 - "Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection." Order ALL the reference details at left...
4.	Anti-Bacterial Agents (Antibiotics)IBA 02/01/2006 - "Relationship of minimal inhibitory concentration and bactericidal activity to efficacy of antibiotics for treatment of ventilator-associated pneumonia." 03/01/2008 - "Previous cultures are not clinically useful for guiding empiric antibiotics in suspected ventilator-associated pneumonia: secondary analysis from a randomized trial." 04/28/2007 - "Among four trials with 1098 patients, oral application of antibiotics did not significantly reduce the incidence of ventilator associated pneumonia (relative risk 0.69, 95% confidence interval 0.41 to 1.18). " 09/01/2009 - "Adjunctive aerosolized antibiotics for treatment of ventilator-associated pneumonia." 04/01/2009 - "SUMMARY: Despite recent promising findings, the widespread use of aerosolized antibiotics to treat ventilator-associated pneumonia cannot be recommended. " Order ALL the reference details at left...
5.	Ceftazidime (Fortum)FDA LinkGeneric 11/01/2007 - "Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review." 02/01/2007 - "Aerosolized ceftazidime prophylaxis against ventilator-associated pneumonia in high-risk trauma patients: results of a double-blind randomized study." 10/01/2009 - "PURPOSE: Ventilator-associated pneumonia caused by Pseudomonas aeruginosa with impaired sensitivity to ceftazidime is frequent in critically ill patients. " 08/01/2002 - "Aerosolized ceftazidime for prevention of ventilator-associated pneumonia and drug effects on the proinflammatory response in critically ill trauma patients." 11/01/2007 - "OBJECTIVE: The objective of this study was to compare the clinical efficacy of ceftazidime administered by continuous infusion and by intermittent infusion in the treatment of ventilator-associated pneumonia (VAP) caused by gram-negative bacteria. " Order ALL the reference details at left...
6.	Vancomycin FDA LinkGeneric 06/01/2009 - "Elevated vancomycin minimum inhibitory concentrations among methicillin-resistant Staphylococcus aureus isolated from patients with ventilator-associated pneumonia at a Connecticut hospital." 01/01/2008 - "Methicillin-resistant (methicillin-resistant) Staphylococcus aureus causes unacceptably high mortality from ventilator-associated pneumonia, even when appropriate early therapy with vancomycin is administered at a dosage of 15 mg/kg every 12 hours. " 01/01/2008 - "Should the currently recommended twice-daily dosing still be considered the most appropriate regimen for treating MRSA ventilator-associated pneumonia with vancomycin?" 08/01/2008 - "For vancomycin, clinical outcome benefits have only been shown in a ventilator-associated pneumonia cohort of critically ill patients. " 08/01/2001 - "Recent studies regarding the use of diagnostic tests for detecting the following epidemiologically important conditions or pathogens are reviewed: vancomycin-resistant enterococci, Legionella, influenza, ventilator-associated pneumonia, Clostridium difficile, bloodstream infection, and tuberculosis." Order ALL the reference details at left...
7.	linezolid (Zyvox)FDA Link 01/01/2004 - "Despite its higher cost, linezolid was cost-effective for treatment of ventilator-associated pneumonia. " 01/01/2004 - "Model estimates were derived from prospective trials of linezolid for ventilator-associated pneumonia and from other studies describing the costs and outcomes for ventilator-associated pneumonia. " 03/01/2009 - "Affect of linezolid in ventilator-associated pneumonia caused by MRSA." 07/01/2005 - "OBJECTIVE: To determine the steady-state plasma pharmacokinetic variables and epithelial lining fluid concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. " 07/01/2005 - "Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia." Order ALL the reference details at left...
8.	doripenem FDA Link 08/15/2009 - "The reduced medical resource use achieved with use of doripenem for treatment of ventilator-associated pneumonia may provide not only clinical benefits to patients but also economic benefits to hospitals and health care systems." 08/15/2009 - "The topics addressed include antimicrobial resistance and the available therapeutic options against gram-negative pathogens, the in vitro activity of doripenem, the efficacy and safety of intravenous infusion of doripenem, and the clinical and economic consequences of ventilator-associated pneumonia. " 08/15/2009 - "The safety and tolerability of intravenous doripenem was evaluated in 1 phase 2 and in 6 phase 3 clinical trials conducted with patients with nosocomial pneumonia, including ventilator-associated pneumonia; complicated intra-abdominal infection; and complicated urinary tract infection. " 08/15/2009 - "In this supplement, researchers in infectious diseases discuss the role of doripenem, a newly approved carbapenem, in the treatment of serious nosocomial infections and review new data on doripenem for the treatment of nosocomial pneumonia, including ventilator-associated pneumonia. " 01/01/2009 - "Doripenem is a new carbapenem, recently approved in the US for the treatment of adults with complicated urinary tract infections (cUTI) or complicated intra-abdominal infections (cIAI), and additionally in the EU for nosocomial pneumonia, including ventilator-associated pneumonia. " Order ALL the reference details at left...
9.	ChlorhexidineIBA 07/01/2009 - "However, in several studies, oral applications of chlorhexidine have reduced the occurrence of ventilator-associated pneumonia. " 03/29/2008 - "[Less ventilator-associated pneumonia after oral decontamination with chlorhexidine; a randomised trial]" 03/01/2009 - "Critical appraisal of: Koeman M, van der Ven AJ, Hak E, et al: Oral decontamination with chlorhexidine reduces the incidence of ventilator-associated pneumonia. " 01/01/2009 - "Prevention of ventilator-associated pneumonia by use of oral chlorhexidine." 02/01/2008 - "Randomized controlled trial and meta-analysis of oral decontamination with 2% chlorhexidine solution for the prevention of ventilator-associated pneumonia." Order ALL the reference details at left...
10.	Piperacillin FDA Link 05/01/2008 - "CONCLUSIONS: A target piperacillin serum concentration of at least 35-40 mg/L is probably required to provide alveolar concentrations exceeding the susceptibility breakpoint for gram-negative bacteria (16 mg/L) during ventilator-associated pneumonia. " 12/01/2006 - "Impact of piperacillin resistance on the outcome of Pseudomonas ventilator-associated pneumonia." 04/15/2002 - "Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms." 03/01/2008 - "The aim of this study is to describe the effect of PE on the serum and subcutaneous tissue pharmacokinetics of piperacillin administered as a continuous infusion in a critically ill 17-year-old patient with Guillain-Barré syndrome and ventilator-associated pneumonia on Days 1 and 4 of antibiotic therapy. " 05/01/2009 - "Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion." Order ALL the reference details at left...

Therapies and Procedures

1.	Artificial Respiration (Mechanical Ventilation) 01/01/2005 - "CONCLUSION: Subglottic secretion drainage appears effective in preventing early-onset ventilator-associated pneumonia among patients expected to require >72 hours of mechanical ventilation." 02/01/2008 - "OBJECTIVE: To review the effectiveness of prone position as compared with supine position, with respect to mortality, improvement in oxygenation, number of days on mechanical ventilation, and ventilator-associated pneumonia. " 02/01/2008 - "There were no significant differences in number of days on mechanical ventilation (two studies, 831 patients; weighted mean difference, -0.42 days; 95% CI, -1.56 to 0.72) or incidence of ventilator-associated pneumonia (three studies, 967 patients; weighted mean difference, 0.78%; 95% CI, 0.40-1.51). " 09/01/2009 - "Observed ventilator-associated pneumonia rates varied across intensive care units from 9.7 to 26.1 of 1000 mechanical ventilation days but the ratio of observed over theoretical ventilator-associated pneumonia rates was >1 in only two intensive care units. " 07/01/2009 - "PATIENTS: One hundred one patients who received mechanical ventilation and who met the criteria for having ventilator-associated pneumonia. " Order ALL the reference details at left...
2.	Mechanical Ventilators (Ventilator) 03/01/2009 - "Efficacy of an expanded ventilator bundle for the reduction of ventilator-associated pneumonia in the medical intensive care unit." 12/01/2004 - "OBJECTIVE: To analyze the efficacy of periodically changing ventilator circuits for decreasing the rate of ventilator-associated pneumonia when a heat and moisture exchanger (HME) is used for humidification. " 06/01/2004 - "There were 874 episodes of ventilator-associated pneumonia at the four hospitals during the 3.5-year study period out of 129,527 ventilator days. " 02/01/1998 - "RESULTS: Eight studies indicate that the interval between ventilator tubing circuit changes can be extended to 7 days without increasing the rate of ventilator-associated pneumonia. " 01/01/1996 - "Prospective, randomized study of ventilator-associated pneumonia in patients with one versus three ventilator circuit changes per week." Order ALL the reference details at left...
3.	Intensive Care (Surgical Intensive Care) 04/01/2007 - "Humidification policies for mechanically ventilated intensive care patients and prevention of ventilator-associated pneumonia: a systematic review of randomized controlled trials." 04/01/2000 - "CONCLUSION: This study illustrates the effectiveness of a multidisciplinary team approach devised to reduce and stabilize ventilator-associated pneumonia rates in a medical-surgical intensive care unit." 08/01/1991 - "This study assessed the incidence, etiology, and consequences of ventilator-associated pneumonia in 1,000 consecutive patients admitted in a medical-surgical intensive care unit (ICU). " 10/01/2009 - "Successful prevention of ventilator-associated pneumonia in an intensive care setting." 10/01/2008 - "Evidence-based guidelines for the prevention of ventilator-associated pneumonia: results of a knowledge test among European intensive care nurses." Order ALL the reference details at left...
4.	Tracheotomy 08/01/2007 - "In summary, the present study demonstrates that tracheotomy is independently associated with decreased risk for ventilator-associated pneumonia." 06/01/2004 - "No data from randomized controlled trials actually support the thesis that tracheotomy reduces the incidence of ventilator-associated pneumonia. " 02/01/2009 - "CONCLUSION: Early tracheotomy in elderly patients is associated with less ventilator-associated pneumonia, more frequent intubations, less total admission time, and a trend toward lower mortality." 02/01/2009 - "OBJECTIVES: To determine if the timing of tracheotomy in elderly patients results in less ventilator associated-pneumonia, mortality, and morbidity. " 02/01/2009 - "Early tracheotomy in elderly patients results in less ventilator-associated pneumonia." Order ALL the reference details at left...
5.	Critical Care 04/01/1995 - "Using a logistic regression model, there were significantly greater odds of developing a ventilator-associated pneumonia in surgical patients (odds ratio 1.77, P = 0.02) and patients in critical care units (odds ratio 1.54, P = 0.05), but no significant risk of ventilator-associated pneumonia in patients in whom circuits were changed at 1-week intervals (odds ratio 0.82, P = 0.22). " 01/01/2008 - "The study conducted by Seligman and coworkers included in the previous issue of Critical Care demonstrates that copeptin is a promising marker to predict outcome in patients with ventilator-associated pneumonia. " 07/01/2007 - "OBJECTIVE: To develop a reliable and valid questionnaire for evaluating critical care nurses' knowledge of evidence-based guidelines for preventing ventilator-associated pneumonia. " 07/01/2007 - "Critical care nurses' knowledge of evidence-based guidelines for preventing ventilator-associated pneumonia: an evaluation questionnaire." 03/01/2007 - "[Incidences of early- and late-onset ventilator-associated pneumonia in a postanesthesia and critical care unit]" Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Ventilator-Associated Pneumonia

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 39 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>